arrow
D

David Piccioni

University of California San Diego
H指数:40
被引数:7,043

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial

Abemaciclib在具有体细胞NF2或CDK途径改变的脑膜瘤中的应用: 2期联盟A071401试验

2026-01-160
OAAI
The University of California San Diego Post-Treatment Glioblastoma (UCSD-PTGBM) annotated multimodal MRI Dataset

加州大学圣地亚哥分校治疗后胶质母细胞瘤(UCSD-PTGBM)注释的多模态MRI数据集

2026-01-060
OAAI
Phase 2 trial of personal dendritic cell vaccines in newly diagnosed glioblastoma: 3-year follow-up and correlations with survival

Bota, D.A.; Piccioni, D.E.; Duma, C.M.; Kesari, S.; Carrillo, J.A.; LaRocca, R.V.; Aiken, R.D.; Taylor, T.H.; Abedi, M.; Robles, R.M.; 等. 新诊断胶质母细胞瘤的个性化树突状细胞疫苗2期试验:3年随访及与生存期的相关性. Hum. Vaccines Immunother. 2025, 21, 2556591. [Google Scholar] [CrossRef]

2025-12-313
PRE
SURGICALLY TARGETED RADIATION THERAPY (START) FOR RECURRENT MENINGIOMA: INITIAL REPORT ON A MULTI-INSTITUTIONAL PROSPECTIVE STUDY

手术靶向放射疗法(START)治疗复发性脑膜瘤:一项多中心前瞻性研究的初步报告

2025-11-010
OAAI
UPDATED RESULTS OF PHASE 3 STELLAR TRIAL: EFLORNITHINE IMPROVES OVERALL SURVIVAL AND BLINDED INDEPENDENT CENTRAL REVIEW DETERMINED PROGRESSION FREE SURVIVAL IN PATIENTS WITH RECURRENT WHO 2021 GRADE 3 IDH-MUTANT ASTROCYTOMA

更新后的III期STELLAR试验结果:依氟鸟氨酸改善2021年WHO分级3级IDH突变型星形细胞瘤患者的总生存期和盲态独立中央审查确定的无进展生存期

2025-11-010
OAAI
Trial in progress update: A phase 1/2 study of intracranial and intravenous multi-dosing of DB107-RRV (formerly Toca 511) and DB107-FC (5-fluorocytosine) in combination with radiation ± temozolomide (TMZ) in patients with newly diagnosed high-grade gliomas (HGGs)

试验进行中更新:一项关于DB107-RRV(原Toca 511)和DB107-FC(5-氟胞嘧啶)颅内及静脉多剂量给药,并与放疗联合±替莫唑胺(TMZ)治疗新诊断的高级别胶质瘤(HGGs)的1/2期研究。

2025-11-010
OAAI
PRIMARY RESULTS OF THE RANDOMIZED CLINICAL TRIAL OF BERUBICIN VS LOMUSTINE IN PATIENTS WITH GLIOBLASTOMA AFTER FAILURE OF PRIMARY THERAPY: DATA ANALYSIS AND FUTURE POSSIBILITIES

随机临床试验的初步结果:在初次治疗失败后的胶质母细胞瘤患者中比较鲁比西丁与洛莫司汀:数据分析与未来可能性

2025-11-010
OAAI
A COMPARATIVE STUDY OF PROTON VS PHOTON VOLUMETRIC MODULATED ARC THERAPY CRANIOSPINAL IRRADIATION FOR SOLID TUMOR LEPTOMENINGEAL CARCINOMATOSIS

质子与光子容积调强弧形疗法在实体瘤软脑膜癌病颅脑脊髓照射中的比较研究

2025-11-010
OAAI
Phase II trial of blood-brain barrier permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma

血脑屏障通透性肽-紫杉醇结合物ANG1005在复发性高级别胶质瘤患者中的II期试验

2024-12-140
OAAI
RECURRENT BRAIN METASTASES (RBM) TREATED WITH SURGICALLY TARGETED RADIATION THERAPY (START): PRELIMINARY SAFETY EVALUATION FROM A MULTI-INSTITUTIONAL PROSPECTIVE REGISTRY
2024-11-110
PRE
TRIALS IN PROGRESS: REGISTRY OF SAFETY & EFFICACY IN ADULTS WITH PRIMARY & METASTATIC INTRACRANIAL TUMORS TREATED WITH START (GAMMATILES (CS-131 SOURCE BRACHY-THERAPY)): NCT04427384
2024-11-110
PRE
PHASE 3 STELLAR STUDY SHOWS EFLORNITHINE IMPROVES OVERALL SURVIVAL (OS) AND PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH RECURRENT 2021 WHO ASTROCYTOMA, IDH-MUTANT GRADE 3
2024-11-110
PRE
CSF TUMOR CELL (CSF-TC) DETECTION, QUANTIFICATION AND BIOMARKER ASSESSMENT HELPS IN CLINICAL MANAGEMENT OF BREAST CANCER AND NON-SMALL CELL LUNG CANCER PATIENTS HAVING LEPTOMENINGEAL DISEASE (FORESEE STUDY, NCT05414123)

CSF肿瘤细胞 (csf-tc) 检测,定量和生物标志物评估有助于患有软脑膜疾病的乳腺癌和非小细胞肺癌患者的临床管理 (FORESEE研究,NCT05414123)

2024-11-110
PRE
THE ONCOGENIC FLIP IN PATIENTS WITH LEPTOMENINGEAL METASTATIC DISEASE (LMD): LONGITUDINAL DETECTION IN CEREBROSPINAL FLUID TUMOR CELLS (CSF-TCS) REVEALS IMPLICATIONS FOR DIFFERENTIAL TREATMENT OF THE LMD TUMOR

脑膜转移性疾病 (LMD) 患者的致癌翻转: 脑脊液肿瘤细胞 (csf-tcs) 的纵向检测揭示了LMD肿瘤的鉴别治疗的意义

2024-11-110
PRE
Low PD-L1 expression, MAP2K2 alterations, and enriched HPV gene signatures characterize brain metastases in head and neck squamous cell carcinoma
2024-10-220
OAAI